Wellington Management Group LLP Has $4.25 Million Holdings in Urogen Pharma $URGN

Wellington Management Group LLP increased its holdings in shares of Urogen Pharma (NASDAQ:URGN) by 15.1% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 115,362 shares of the company’s stock after acquiring an additional 15,147 shares during the period. Wellington Management Group LLP owned about 0.24% of Urogen Pharma worth $4,245,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Persistent Asset Partners Ltd acquired a new position in Urogen Pharma in the second quarter worth $66,000. Quantbot Technologies LP bought a new stake in shares of Urogen Pharma during the second quarter worth $78,000. Russell Investments Group Ltd. increased its stake in shares of Urogen Pharma by 1,594.4% in the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock valued at $66,000 after buying an additional 3,125 shares in the last quarter. Osaic Holdings Inc. raised its holdings in shares of Urogen Pharma by 491.2% in the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after buying an additional 3,070 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in Urogen Pharma by 422.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock worth $94,000 after buying an additional 5,571 shares in the last quarter. 91.29% of the stock is owned by institutional investors and hedge funds.

Urogen Pharma Trading Up 2.7%

Shares of NASDAQ:URGN opened at $45.00 on Thursday. The stock has a market capitalization of $2.20 billion, a P/E ratio of -22.73 and a beta of 1.57. Urogen Pharma has a 1-year low of $15.86 and a 1-year high of $50.81. The business has a 50-day moving average price of $43.16 and a two-hundred day moving average price of $31.31.

Urogen Pharma (NASDAQ:URGN) last issued its earnings results on Wednesday, August 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The firm had revenue of $72.46 million for the quarter, compared to the consensus estimate of $63.55 million. As a group, equities analysts predict that Urogen Pharma will post -0.2 EPS for the current year.

Insider Activity at Urogen Pharma

In other Urogen Pharma news, General Counsel Jason Smith sold 1,519 shares of Urogen Pharma stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $42.54, for a total transaction of $64,618.26. Following the completion of the sale, the general counsel owned 53,141 shares of the company’s stock, valued at approximately $2,260,618.14. The trade was a 2.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mark Schoenberg sold 60,677 shares of the company’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $47.05, for a total transaction of $2,854,852.85. Following the sale, the insider owned 59,086 shares of the company’s stock, valued at $2,779,996.30. The trade was a 50.66% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 83,067 shares of company stock worth $3,706,954 over the last 90 days. 4.80% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have commented on URGN. Oppenheimer increased their price objective on shares of Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a report on Thursday, July 16th. Jefferies Financial Group reiterated a “buy” rating on shares of Urogen Pharma in a research report on Thursday. TD Cowen increased their price target on shares of Urogen Pharma from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. UBS Group reissued a “buy” rating on shares of Urogen Pharma in a report on Thursday, July 9th. Finally, The Goldman Sachs Group restated a “neutral” rating and issued a $44.00 price objective on shares of Urogen Pharma in a research report on Wednesday, July 15th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $50.38.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.